A large Swedish population-based study has shown that 15-year prostate-cancer-related mortality rates are negligible for men with low-risk cancers treated noncuratively, but significant for those with intermediate-risk and high-risk tumours. Such data support current trends towards active surveillance for low-risk disease and aggressive multimodal treatment for advanced carcinomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rider, J. R. et al. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2012.08.001.
Abdollah, F. et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur. Urol. 60, 920–930 (2011).
Abdollah, F. et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur. Urol. 59, 88–95 (2011).
Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203–213 (2012).
Novara, G. et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur. Urol. 62, 431–452 (2012).
Ficarra, V. et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur. Urol. 62, 418–430 (2012).
Ficarra, V. et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur. Urol. 62, 405–417 (2012).
Mottet, N. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59, 572–583 (2011).
Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61–71 (2011).
Briganti, A. et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: results of a matched analysis. Eur. Urol. 59, 832–840 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Novara, G., Ficarra, V. Epidemiologic studies and changing clinical practice. Nat Rev Urol 9, 676–677 (2012). https://doi.org/10.1038/nrurol.2012.203
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.203